scholarly journals Vitamin D supplementation and inflammatory and metabolic biomarkers in patients with knee osteoarthritis: post hoc analysis of a randomised controlled trial – Corrigendum

2018 ◽  
Vol 121 (1) ◽  
pp. 118-119
Author(s):  
Shuang Zheng ◽  
Bing Wang ◽  
Weihu Han ◽  
Zhaohua Zhu ◽  
Xia Wang ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomised Controlled Trial ◽  
Knee Osteoarthritis ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Post Hoc Analysis ◽  
Randomised Controlled ◽  
Post Hoc ◽  
Metabolic Biomarkers

scholarly journals Vitamin D supplementation and inflammatory and metabolic biomarkers in patients with knee osteoarthritis: post hoc analysis of a randomised controlled trial

2018 ◽  
Vol 120 (1) ◽  
pp. 41-48 ◽  
Author(s):  
Shuang Zheng ◽  
Bing Wang ◽  
Weiyu Han ◽  
Zhaohua Zhu ◽  
Xia Wang ◽  
...  
Keyword(s):  
Vitamin D ◽  
Knee Osteoarthritis ◽  
Vitamin D Deficiency ◽  
Controlled Trial ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Knee Oa ◽  
Symptomatic Knee ◽  
Post Hoc ◽  
Metabolic Biomarkers

AbstractThe aim of this study was to determine whether vitamin D supplementation and maintaining vitamin D sufficiency are associated with changes in inflammatory and metabolic biomarkers in patients with knee osteoarthritis (OA) and vitamin D deficiency. A total of 413 participants with symptomatic knee OA and vitamin D deficiency were enrolled in a randomised, placebo-controlled trial and received 1·25 mg vitamin D3 or placebo monthly for 24 months across two sites. In this post hoc analysis, 200 participants from one site (ninety-four from the placebo group and 106 from the vitamin D group; mean age 63·1 (sd 7·3) years, 53·3 % women) were randomly selected for measurement of serum levels of inflammatory and metabolic biomarkers at baseline and 24 months using immunoassays. In addition, participants were classified into two groups according to serum 25-hydroxyvitamin D (25(OH)D) levels at months 3 and 24: (1) not consistently sufficient (25(OH)D≤50 nmol/l at either month 3 or 24, n 61), and (2) consistently sufficient (25(OH)D>50 nmol/l at both months 3 and 24, n 139). Compared with placebo, vitamin D supplementation had no significant effect on change in serum high-sensitive C-reactive protein, IL-6, IL-8, IL-10, leptin, adiponectin, resistin, adipsin and apelin. Being consistently vitamin D sufficient over 2 years was also not associated with changes in these biomarkers compared with not being consistently sufficient. Vitamin D supplementation and maintaining vitamin D sufficiency did not alter serum levels of inflammatory and metabolic biomarkers over 2 years in knee OA patients who were vitamin D insufficient, suggesting that they may not affect systemic inflammation in knee OA patients.

scholarly journals Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1465
Author(s):  
Taisuke Akutsu ◽  
Eisaku Ito ◽  
Mitsuo Narita ◽  
Hironori Ohdaira ◽  
Yutaka Suzuki ◽  
...  
Keyword(s):  
Vitamin D ◽  
Digestive Tract ◽  
Multivariate Analyses ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Digestive Tract Cancer ◽  
Post Hoc Analysis ◽  
Tract Cancer ◽  
Potential Biomarker ◽  
Post Hoc

Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; p = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse.

scholarly journals Is there an association between subjective sleep quality and daily delirium occurrence in critically ill adults? A post hoc analysis of a randomised controlled trial

2020 ◽  
Vol 7 (1) ◽  
pp. e000576 ◽  
Author(s):  
Matthew S Duprey ◽  
John W Devlin ◽  
Yoanna Skrobik
Keyword(s):  
Regression Analysis ◽  
Intensive Care ◽  
Randomised Controlled Trial ◽  
Sleep Quality ◽  
Controlled Trial ◽  
Predictive Analysis ◽  
Icu Patients ◽  
Post Hoc Analysis ◽  
Randomised Controlled ◽  
Post Hoc

ObjectivesWhether and how delirium and sleep quality in the intensive care unit (ICU) are linked remains unclear. A recent randomised trial reported nocturnal low-dose dexmedetomidine (DEX) significantly reduces incident ICU delirium. Leeds Sleep Evaluation Questionnaire (LSEQ) scores were similar between intervention (DEX; n=50) and control (placebo (PLA); n=50) groups. We measured the association between morning LSEQ and delirium occurrence in the prior 24 hours (retrospective analysis) and the association between morning LSEQ and delirium occurrence in the following 24 hours (predictive analysis).DesignPost hoc analysis of randomised controlled trial data.ParticipantsAdult ICU patients (n=100) underwent delirium screening twice a day using the Intensive Care Delirium Screening Checklist (ICDSC) if Richmond Agitation Sedation Scale (RASS) was ≥−3 and patient-reported sleep quality evaluations at 09:00 daily with the LSEQ if RASS was ≥−1.OutcomesThe analysis included all 24-hour study periods with LSEQ documentation and matched delirium screening in coma-free patients. Separate logistic regression models controlling for age, baseline Acute Physiology and Chronic Health Evaluation II score and DEX/PLA allocation evaluated the association between morning LSEQ and delirium occurrence for both retrospective and predictive analyses.ResultsThe 100 patients spent 1115 24-hour periods in the ICU. Coma, delirium and no delirium occurred in 130 (11.7%), 114 (10.2%) and 871 (78.1%), respectively. In the retrospective analysis, when an LSEQ result was preceded by an ICDSC result (439/985 (44.6%) 24-hour periods), delirium occurred during 41/439 (9.3%) periods. On regression analysis, the LSEQ score had no relationship to prior delirium occurrence (OR (per every 1 point average LSEQ change) 0.97, 95% CI 0.72 to 1.31). For the predictive analysis, among the 387/985 (39.1%) 24-hour periods where an LSEQ result was followed by an ICDSC result, delirium occurred during 56/387 (14.5%) periods. On regression analysis, the LSEQ score did not predict subsequent delirium occurrence (OR (per 1 point LSEQ change) 1.02, 95% CI 0.99 to 1.05).ConclusionsThe sleep quality ICU patients perceive neither affects nor predicts delirium occurrence.Trial registration numberNCT01791296

Sign in / Sign up

Export Citation Format

Share Document